Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults

What is the effect of the bivalent respiratory syncytial virus prefusion F protein–based (RSVpreF) vaccine on cardiorespiratory and cardiovascular hospitalizations?In this randomized clinical trial including 131 276 adults aged 60 years or older, the incidence of all-cause cardiorespiratory hospitalization was significantly lower in the RSVpreF group compared with the control group (26.3 vs 29.2 events per 1000 participant-years). The incidence of all-cause cardiovascular hospitalization was 16.4 vs 17.7 events per 1000 participant-years, a nonsignificant difference.Among adults aged 60 years or older, use of the RSVpreF vaccine prevented cardiorespiratory hospitalizations.

Corresponding Author: Tor Biering-Sørensen, MD, MSc, MPH, PhD, Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, Gentofte Hospitalsvej 8, 3.th., 2900 Hellerup, Denmark (tor.biering@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.